Both in Pharmaceuticals
Erasca vs Ligand Pharmaceuticals
Over the past year ERAS returned +545.5% and LGND returned +66.9%; their daily moves had a correlation of 0.18.
ERAS +545.5% LGND +66.9%Growth of $1, one year, split-adjusted
| Metric | ERAS | LGND |
|---|---|---|
| Price | $14.91 | $316.13 |
| Market cap | $5.21B | $6.32B |
| Today | +1.84% | +0.83% |
| 1 month | +4.3% | +6.5% |
| 6 months | +36.8% | +35.9% |
| Year to date | +300.8% | +67.2% |
| 1 year | +526.5% | +65.3% |
| Revenue growth (YoY) | — | −31.8% |
| Gross margin | — | 83.7% |
| Net margin | — | −36.2% |
| P/E (TTM) | — | 122.9× |
| Price / sales | — | 24.9× |
| Net cash | $268.7M | -$653.3M |
| Dividend yield | — | — |
| Volatility (60d) | 59.7% | 29.3% |
| Short % of float | 14.5% | 13.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).